ArticleJournal of the American Geriatrics Society2020
Motoric Cognitive Risk Syndrome in Polypharmacy.
Article in Journal of the American Geriatrics Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Cognitive and physical functions among Chinese community-dwelling older adults with motoric cognitive risk syndrome: A prospective cohort study.International journal of nursing sciences · 2025Article
- From Dual Decline to Clinical Consequences: Mechanistic Pathways and Health Outcomes of Motoric Cognitive Risk Syndrome.Aging and disease · 2025Review
- A nomogram-based prediction model for motoric cognitive risk syndrome in patients with coronary artery disease: a cross-sectional study.Aging clinical and experimental research · 2025Article
- Motoric cognitive risk syndrome: A review of fall risk assessment and management strategies.World journal of psychiatry · 2025Review
- Current status and influencing factors of motor-cognitive risk syndrome in the older rural Chinese population: a cross-sectional study.Frontiers in public health · 2025Article
- Evaluation criteria for diagnosing motoric cognitive risk syndrome: a scoping review.Dementia & neuropsychologia · 2025Review
- Cardiometabolic and panvascular multimorbidity associated with motoric cognitive risk syndrome in older adults.Journal of geriatric cardiology : JGC · 2024Article
- Article
- Incidence of Motoric Cognitive Risk Syndrome and Associated Factors in Older Adults in Türkiye.Balkan medical journal · 2024Article
- Reward System Dysfunction and the Motoric-Cognitive Risk Syndrome in Older Persons.Biomedicines · 2022Article
- Sarcopenia and motoric cognitive risk syndrome: a moderated mediation model.BMC geriatrics · 2022Article
- Motoric Cognitive Risk Syndrome: Symptoms, Pathology, Diagnosis, and Recovery.Frontiers in aging neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesRisk factors for motoric cognitive risk syndrome (MCR), a predementia syndrome characterized by slow gait and cognitive complaints, have been identified, but few are reversible. Polypharmacy is a potentially reversible risk factor for cognitive decline, but the relationship between MCR and polypharmacy has not been examined. Our aim was to compare the epidemiology of MCR and polypharmacy.
designCross-sectional.
settingCommunity-based Health and Retirement Study cohort.
participantsA total of 1119 adults 65 years and older (mean age = 74.7 ± 7.0 y; 59% female). MEASUREMENTS: Polypharmacy is defined as the use of five or more regularly scheduled medications. MCR is defined as cognitive complaints and slow gait in an individual without dementia.
resultsThe prevalence of MCR among 417 participants with polypharmacy was 10%; it was 6% among 702 participants without polypharmacy. The odds of meeting MCR criteria in those with polypharmacy was 1.8 (confidence interval = 1.0-3.0; P = .035) compared with those without polypharmacy, even after adjusting for high-risk medication use.
conclusionOur results show the coexistence of MCR and polypharmacy in older adults, suggesting a potentially modifiable risk factor for dementia. J Am Geriatr Soc 68:1072-1077, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.